<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="293">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01402063</url>
  </required_header>
  <id_info>
    <org_study_id>BrUOG 244</org_study_id>
    <nct_id>NCT01402063</nct_id>
  </id_info>
  <brief_title>PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation</brief_title>
  <official_title>PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maine Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To obtain preliminary data in a randomized phase II study whether PPX/RT improves
      progression-free survival as compared to temozolomide/RT for patients with GBM without MGMT
      methylation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the toxicities of PPX/RT To evaluate neuro-cognitive functional assessments of
      patients with GBM receiving PPX/RT To obtain preliminary data in a randomized phase II study
      whether PPX/RT improves overall survival as compared to temozolomide /RT for patients with
      GBM without MGMT methylation to facilitate planning a phase III study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>evaluate the toxicities of PPX/RT at years 1 and 2 of the trial</measure>
    <time_frame>At years 1 and 2</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients will be evaluated throughout their treatment however a cumulative evaluation will be conducted at years 1 and 2 of the trial</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>radiation plus PPX(CT2103</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation therapy, Monday through Friday, for 6 weeks for a total of 30 treatments
+ intravenous PPX every week x 6 weeks for a total of 6 treatments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiation + Temozolomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation therapy, Monday through Friday, for 6 weeks for a total of 30 treatments
+ Daily oral temozolomide(TMZ) (7 days) x 6 wks for a total of 42 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PPX (CT2103)</intervention_name>
    <description>XRT: 60 Gy at 2 Gy/fraction x 30 fractions PPX: 50 mg/m2/week x 6 weeks during radiation Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum.</description>
    <arm_group_label>radiation plus PPX(CT2103</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide, 75 mg/m2/day, 7 days per week, from the first to the last day of radiotherapy Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum</description>
    <arm_group_label>radiation + Temozolomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven diagnosis of glioblastoma or gliosarcoma (WHO grade IV)

          -  GBM must have unmethylated MGMT as determined by central laboratory

          -  Diagnosis of GBM must be made by biopsy or surgical excision, either partial or
             complete; as long as there is sufficient tissue to determine MGMT status

          -  No prior chemotherapy or radiation for brain tumor

          -  Must be able to tolerate brain MRIs.

             *A diagnostic contrast-enhanced MRI must be performed postoperatively within 42 days
             prior to study registration.

          -  KPS &gt;60.

          -  Age &gt; 18

          -  Life expectancy of at least 3 months.

          -  Absolute neutrophil count &gt; 1500/mm3, Platelets &gt; 100,000/mm,

          -  Creatinine &lt; 2 x ULN

          -  ALT or AST &lt; 3 x upper limit of normal (ULN) and total bilirubin &lt; 1.5x ULN.

          -  Patients with a prior history of low grade glioma who did not receive prior radiation
             or chemotherapy  with transformation to grade IV brain tumor are eligible.

          -  Women must be non-lactating, and surgically sterile, post-menopausal or have a
             negative serum pregnancy test and agree to use adequate birth control. Males must
             agree to use adequate birth control.

          -  Voluntary, signed informed consent.

        Exclusion Criteria:

          -  Acute infection or other medical condition that would impair study treatment

          -  No other active invasive malignancy unless disease free for at least 3 years.

          -  Prior temozolomide or PPX.

          -  Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment are
             not permitted.

          -  Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in
             overlap of radiation fields.

          -  No diffuse leptomeningeal disease, or gliomatosis cerebri.

          -  Use of any other experimental chemotherapy drug within the 60 days prior to
             randomization and during the trial. (Use of a non-chemotherapy investigational agent
             must be approved by the Brown University Oncology Group)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Safran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BrUOG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suriya Jenapaylan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lifespan Hospitals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kayla Rosati</last_name>
    <phone>401-863-3000</phone>
    <email>kayla_rosati@brown.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>kayla rosati</last_name>
      <phone>401-863-3000</phone>
      <email>kayla_rosati@brown.edu</email>
    </contact>
    <investigator>
      <last_name>Santosh Kesari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>kayla rosati</last_name>
      <phone>401-863-3000</phone>
      <email>kayla_rosati@brown.edu</email>
    </contact>
    <investigator>
      <last_name>Devon Evans, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMASS Medical Center Cancer Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>kayla rosati</last_name>
      <phone>401-863-3000</phone>
      <email>kayla_rosati@brown.edu</email>
    </contact>
    <investigator>
      <last_name>Shakeeb Yunus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PSU</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>kayla rosati</last_name>
      <phone>401-863-3000</phone>
      <email>kayla_rosati@brown.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Glantz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>alyson santaniello</last_name>
      <phone>401-444-7698</phone>
      <email>asantaniello@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Howard Safran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suriya Jenapaylan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayla Rosati</last_name>
      <phone>401-863-3000</phone>
      <email>kayla_rosati@brown.edu</email>
    </contact>
    <investigator>
      <last_name>Maciej Mrugala, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 9, 2013</lastchanged_date>
  <firstreceived_date>July 8, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>howard safran</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Brain Tumors</keyword>
  <keyword>Glioblastoma Multiforme</keyword>
  <keyword>GBM</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
